Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBC
Status:
Active, not recruiting
Trial end date:
2026-01-30
Target enrollment:
Participant gender:
Summary
International, randomised, open label, neo-adjuvant phase II trial in women with newly
diagnosed, non-metastatic, high-risk (node positive and/or tumour size ≥ 2cm), triple
negative breast cancer. The study aims to evaluate the effects of adding ipatasertib to
chemotherapy and atezolizumab in patients with and without PI3CA/AKT1/PTEN genetic
alterations.